Apalutamide - Janssen Research and Development

Drug Profile

Apalutamide - Janssen Research and Development

Alternative Names: ARN-509; JNJ-56021927; JNJ-927

Latest Information Update: 26 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California System
  • Developer Case Comprehensive Cancer Center; Dana-Farber Cancer Institute; Institut Paoli-Calmettes; Janssen Research & Development; Singapore General Hospital
  • Class Antiandrogens; Antihormones; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists; Hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Prostate cancer

Most Recent Events

  • 28 Dec 2017 NRG Oncology and National Cancer Institute plan a phase II trial in Prostate cancer (Late-stage disease) in USA in February 2018 (NCT03371719)
  • 21 Dec 2017 Apalutamide receives priority review status for Prostate cancer (Hormone refractory, Second-line therapy or greater)
  • 21 Dec 2017 FDA assigns PDUFA action date of 01/04/2018 for apalutamide for non-metastatic castration-resistant Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top